The FDA requires stricter bioequivalence standards for Narrow Therapeutic Index (NTI) drugs like warfarin and phenytoin, using tighter 90-111% limits and replicate studies to ensure safety. These rules prevent dangerous fluctuations in blood levels that can occur with standard generic substitutions.
11
